MedTrace Logo

Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension

NCT00004268 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension.

II. Assess the quality of life in these patients with this treatment regimen.

Conditions

  • Orthostatic Hypotension

Interventions

DRUG

midodrine

Sponsors & Collaborators

  • Roberts Pharmaceutical

    collaborator INDUSTRY

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Horacio Kaufmann · Roberts Pharmaceutical

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004268 on ClinicalTrials.gov